Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Esperion Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ESPR
Nasdaq
2834
www.esperion.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Esperion Therapeutics, Inc.
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
- Jan 14th, 2025 2:07 pm
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
- Jan 9th, 2025 1:00 pm
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2025 1:00 pm
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
- Dec 18th, 2024 12:00 pm
Esperion Announces $210 Million Convertible Debt Financing
- Dec 13th, 2024 11:00 am
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
- Dec 12th, 2024 1:00 pm
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
- Dec 3rd, 2024 3:06 pm
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
- Dec 2nd, 2024 1:00 pm
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
- Nov 26th, 2024 1:00 pm
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
- Nov 21st, 2024 1:00 pm
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
- Nov 18th, 2024 3:30 pm
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Nov 8th, 2024 9:15 pm
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
- Nov 8th, 2024 7:08 am
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
- Nov 7th, 2024 3:58 pm
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
- Nov 7th, 2024 12:10 pm
Esperion Therapeutics: Q3 Earnings Snapshot
- Nov 7th, 2024 11:08 am
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
- Nov 7th, 2024 11:00 am
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
- Nov 4th, 2024 1:00 pm
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Oct 31st, 2024 2:01 pm
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
- Oct 31st, 2024 12:00 pm
Scroll